Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

China · Delayed Price · Currency is CNY

8.18

-0.34 (-3.99%)

At close: Sep 11, 2026

Market Cap	19.02B -25.7%
Revenue (ttm)	4.37B -11.1%
Net Income	591.66M -45.7%
EPS	0.26 -46.8%
Shares Out	2.23B
PE Ratio	32.85
Forward PE	20.78
Dividend	0.17 (2.04%)
Ex-Dividend Date	Apr 29, 2026

Volume	25,121,160
Open	8.44
Previous Close	8.52
Day's Range	8.11 - 8.60
52-Week Range	7.69 - 12.90
Beta	0.01
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About SHE:301301

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. It offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxychol... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2010

Employees 3,126

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301301

Full Company Profile

Financial Performance

In 2025, SHE:301301's revenue was 4.62 billion, a decrease of -19.83% compared to the previous year's 5.76 billion. Earnings were 769.01 million, a decrease of -45.08%.

Financial Statements